{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:31:55Z","timestamp":1785461515760,"version":"3.56.0"},"publisher-location":"Cham","reference-count":46,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030732332","type":"print"},{"value":"9783030732349","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-73234-9_22","type":"book-chapter","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T20:03:06Z","timestamp":1641240186000},"page":"347-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nanomicellar Curcumin Supplementation Improves the Clinical Manifestations of HAM\/TSP Patients"],"prefix":"10.1007","author":[{"given":"Asadollah","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi Zamanian","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Poursina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Hampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Akbarien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Boostani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshang","family":"Rafatpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"22_CR1","doi-asserted-by":"crossref","unstructured":"Gessain, A., & Cassar, O. (2012). Epidemiological aspects and world distribution of HTLV-1 infection. Frontiers in Microbiology, 3388.","DOI":"10.3389\/fmicb.2012.00388"},{"issue":"3","key":"22_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1128\/CMR.00063-09","volume":"23","author":"DU Goncalves","year":"2010","unstructured":"Goncalves, D. U., Proietti, F. A., Ribas, J. G., Araujo, M. G., Pinheiro, S. R., Guedes, A. C., et al. (2010). Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clinical Microbiology Reviews, 23(3), 577\u2013589.","journal-title":"Clinical Microbiology Reviews"},{"issue":"3","key":"22_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcv.2011.07.004","volume":"52","author":"H Rafatpanah","year":"2011","unstructured":"Rafatpanah, H., Hedayati-Moghaddam, M. R., Fathimoghadam, F., Bidkhori, H. R., Shamsian, S. K., Ahmadi, S., et al. (2011). High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. Journal of Clinical Virology, 52(3), 172\u2013176.","journal-title":"Journal of Clinical Virology"},{"key":"22_CR4","doi-asserted-by":"crossref","unstructured":"Nozuma S, Jacobson S (2019) Neuroimmunology of human T-Lymphotropic virus type 1-associated myelopathy\/tropical spastic Paraparesis. Front Microbiol 10885.","DOI":"10.3389\/fmicb.2019.00885"},{"issue":"1","key":"22_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12977-019-0499-5","volume":"16","author":"Y Enose-Akahata","year":"2019","unstructured":"Enose-Akahata, Y., & Jacobson, S. (2019). Immunovirological markers in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Retrovirology, 16(1), 35.","journal-title":"Retrovirology"},{"issue":"12","key":"22_CR6","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(06)70628-7","volume":"5","author":"AQ Araujo","year":"2006","unstructured":"Araujo, A. Q., & Silva, M. T. (2006). The HTLV-1 neurological complex. Lancet Neurology, 5(12), 1068\u20131076.","journal-title":"Lancet Neurology"},{"key":"22_CR7","doi-asserted-by":"crossref","unstructured":"Enose-Akahata, Y., Vellucci, A., & Jacobson, S. (2017). Role of HTLV-1 tax and HBZ in the pathogenesis of HAM\/TSP. Frontiers in Microbiology, 82563.","DOI":"10.3389\/fmicb.2017.02563"},{"issue":"1","key":"22_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12977-020-0511-0","volume":"17","author":"M Matsuoka","year":"2020","unstructured":"Matsuoka, M., & Mesnard, J. M. (2020). HTLV-1 bZIP factor: The key viral gene for pathogenesis. Retrovirology, 17(1), 2.","journal-title":"Retrovirology"},{"issue":"4","key":"22_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka, M., & Jeang, K.-T. (2007). Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews Cancer, 7(4), 270\u2013280.","journal-title":"Nature Reviews Cancer"},{"key":"22_CR10","doi-asserted-by":"crossref","unstructured":"Karimi M, Mohammadi H, Hemmatzadeh M, Mohammadi A, Rafatpanah H, Baradaran B (2017) Role of the HTLV-1 viral factors in the induction of apoptosis. Biomed Pharmacother, 85, 334\u2013347.","DOI":"10.1016\/j.biopha.2016.11.034"},{"issue":"2","key":"22_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/1389200024605082","volume":"3","author":"C Murr","year":"2002","unstructured":"Murr, C., Widner, B., Wirleitner, B., & Fuchs, D. (2002). Neopterin as a marker for immune system activation. Current Drug Metabolism, 3(2), 175\u2013187.","journal-title":"Current Drug Metabolism"},{"issue":"1","key":"22_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2009.05.008","volume":"287","author":"R Sucher","year":"2010","unstructured":"Sucher, R., Schroecksnadel, K., Weiss, G., Margreiter, R., Fuchs, D., & Brandacher, G. (2010). Neopterin, a prognostic marker in human malignancies. Cancer Letters, 287(1), 13\u201322.","journal-title":"Cancer Letters"},{"issue":"2","key":"22_CR13","first-page":"109","volume":"4","author":"KK Tsolaki","year":"2001","unstructured":"Tsolaki, K. K., Zaphiriou, D., Grammaticos, P., & Dedussi, E. (2001). Are CSF neopterin levels a marker of disease activity in multiple sclerosis? Nuclear Medicine Review. Central & Eastern Europe, 4(2), 109\u2013111.","journal-title":"Nuclear Medicine Review. Central & Eastern Europe"},{"issue":"Suppl 5S","key":"22_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10072-003-0180-5","volume":"24","author":"F Bagnato","year":"2003","unstructured":"Bagnato, F., Durastanti, V., Finamore, L., Volante, G., & Millefiorini, E. (2003). Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurological Sciences, 24(Suppl 5S), 301\u2013304.","journal-title":"Neurological Sciences"},{"issue":"5","key":"22_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1600-0404.1987.tb05458.x","volume":"75","author":"S Fredrikson","year":"1987","unstructured":"Fredrikson, S., Link, H., & Eneroth, P. (1987). CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurologica Scandinavica, 75(5), 352\u2013355.","journal-title":"Acta Neurologica Scandinavica"},{"key":"22_CR16","doi-asserted-by":"crossref","unstructured":"Hagberg, L., Cinque, P., Gisslen, M., Brew, B. J., Spudich, S., Bestetti, A., et al. (2010). Cerebrospinal fluid neopterin: An informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Research and Therapy, 715\u2013715.","DOI":"10.1186\/1742-6405-7-15"},{"issue":"2","key":"22_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.molimm.2004.06.017","volume":"42","author":"B Wirleitner","year":"2005","unstructured":"Wirleitner, B., Schroecksnadel, K., Winkler, C., & Fuchs, D. (2005). Neopterin in HIV-1 infection. Molecular Immunology, 42(2), 183\u2013194.","journal-title":"Molecular Immunology"},{"issue":"6","key":"22_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1086\/427877","volume":"40","author":"D Mildvan","year":"2005","unstructured":"Mildvan, D., Spritzler, J., Grossberg, S. E., Fahey, J. L., Johnston, D. M., Schock, B. R., et al. (2005). Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clinical Infectious Diseases, 40(6), 853\u2013858.","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"22_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1089\/08892220050058380","volume":"16","author":"A Lezin","year":"2000","unstructured":"Lezin, A., Buart, S., Smadja, D., Akaoka, H., Bourdonne, O., Perret-Liaudet, A., et al. (2000). Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: Preferential presence in HTLV type I-infected neurologic patients versus healthy virus carriers. AIDS Research and Human Retroviruses, 16(10), 965\u2013972.","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"19","key":"22_CR20","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.2169\/internalmedicine.52.0869","volume":"52","author":"M Nagai","year":"2013","unstructured":"Nagai, M., Tsujii, T., Iwaki, H., Nishikawa, N., & Nomoto, M. (2013). Cerebrospinal fluid neopterin, but not osteopontin, is a valuable biomarker for the treatment response in patients with HTLV-I-associated myelopathy. Internal Medicine, 52(19), 2203\u20132208.","journal-title":"Internal Medicine"},{"key":"22_CR21","doi-asserted-by":"crossref","unstructured":"Kahkhaie, K. R., Mirhosseini, A., Aliabadi, A., Mohammadi, A., Mosavi, M. J., Haftcheshmeh, S. M., et al. (2019). Curcumin: A modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology,\u00a027(5), 885\u2013900.","DOI":"10.1007\/s10787-019-00607-3"},{"key":"22_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2018.12.005","volume":"66","author":"A Mohammadi","year":"2019","unstructured":"Mohammadi, A., Blesso, C. N., Barreto, G. E., Banach, M., Majeed, M., & Sahebkar, A. (2019). Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent. Journal of Nutritional Biochemistry, 66, 1\u201316.","journal-title":"Journal of Nutritional Biochemistry"},{"issue":"7","key":"22_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.autrev.2019.05.012","volume":"18","author":"K Rahimi","year":"2019","unstructured":"Rahimi, K., Ahmadi, A., Hassanzadeh, K., Soleimani, Z., Sathyapalan, T., Mohammadi, A., et al. (2019). Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states. Autoimmunity Reviews, 18(7), 738\u2013748.","journal-title":"Autoimmunity Reviews"},{"issue":"6","key":"22_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2174\/1381612822666161006151605","volume":"23","author":"M Ghandadi","year":"2017","unstructured":"Ghandadi, M., & Sahebkar, A. (2017). Curcumin: An effective inhibitor of interleukin-6. Current Pharmaceutical Design, 23(6), 921\u2013931.","journal-title":"Current Pharmaceutical Design"},{"key":"22_CR25","doi-asserted-by":"crossref","unstructured":"Ghasemi, F., Shafiee, M., Banikazemi, Z., Pourhanifeh, M.H., Khanbabaei, H., Shamshirian, A., et al. (2019). Curcumin inhibits NF-kB and Wnt\/\u03b2-catenin pathways in cervical cancer cells. Pathology Research and Practice, 215(10), art. no. 152556.","DOI":"10.1016\/j.prp.2019.152556"},{"issue":"4","key":"22_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40291-016-0202-7","volume":"20","author":"AA Momtazi","year":"2016","unstructured":"Momtazi, A. A., Derosa, G., Maffioli, P., Banach, M., & Sahebkar, A. (2016). Role of microRNAs in the therapeutic effects of curcumin in non-Cancer diseases. Molecular Diagnosis and Therapy, 20(4), 335\u2013345.","journal-title":"Molecular Diagnosis and Therapy"},{"issue":"1","key":"22_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/jcp.25756","volume":"233","author":"Y Panahi","year":"2018","unstructured":"Panahi, Y., Ahmadi, Y., Teymouri, M., Johnston, T. P., & Sahebkar, A. (2018). Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms. Journal of Cellular Physiology, 233(1), 141\u2013152.","journal-title":"Journal of Cellular Physiology"},{"issue":"7","key":"22_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1055\/s-0044-101752","volume":"68","author":"Y Panahi","year":"2018","unstructured":"Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Simental-Mend\u00eda, L. E., Majeed, M., et al. (2018). Effects of Curcuminoids plus Piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled trial. Drug Research, 68(7), 403\u2013409.","journal-title":"Drug Research"},{"key":"22_CR29","doi-asserted-by":"crossref","unstructured":"Bianconi, V., Sahebkar, A., Atkin, S.L., & Pirro, M. (2018). The regulation and importance of monocyte chemoattractant protein-1. Current Opinion in Hematology, 25(1), 44\u201351.","DOI":"10.1097\/MOH.0000000000000389"},{"issue":"3","key":"22_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/biof.1344","volume":"43","author":"M Teymouri","year":"2017","unstructured":"Teymouri, M., Pirro, M., Johnston, T. P., & Sahebkar, A. (2017). Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. BioFactors, 43(3), 331\u2013346.","journal-title":"BioFactors"},{"key":"22_CR31","doi-asserted-by":"crossref","unstructured":"Soleimani, V., Sahebkar, A., & Hosseinzadeh, H. (2018). Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review. Phytother Res, 32(6), 985\u2013995.","DOI":"10.1002\/ptr.6054"},{"issue":"4","key":"22_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","volume":"46","author":"S Izumo","year":"1996","unstructured":"Izumo, S., Goto, I., Itoyama, Y., Okajima, T., Watanabe, S., Kuroda, Y., et al. (1996). Interferon-alpha is effective in HTLV-I-associated myelopathy: A multicenter, randomized, double-blind, controlled trial. Neurology, 46(4), 1016\u20131021.","journal-title":"Neurology"},{"key":"22_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.biopha.2016.11.050","volume":"85","author":"A Mohammadi","year":"2017","unstructured":"Mohammadi, A., Fazeli, B., Taheri, M., Sahebkar, A., Poursina, Z., Vakili, V., et al. (2017). Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients. Biomedicine & Pharmacotherapy, 85, 457\u2013462.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"22_CR34","doi-asserted-by":"crossref","unstructured":"Poursina, Z., Mohammadi, A., Yazdi, S. Z., Humpson, I., Vakili, V., Boostani, R., et al. (2019). Curcumin increased the expression of c-FLIP in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients. Journal of Cellular Biochemistry,\u00a0120(9), 15740\u201315745.\u00a0","DOI":"10.1002\/jcb.28843"},{"key":"22_CR35","doi-asserted-by":"crossref","unstructured":"Mohammadi, A., Fazeli, B., Poursina, Z., Tehranian, F., Vakili, V., Boostani, R., et al. (2019). HTLV-1-infected asymptomatic carriers compared to HAM\/TSP patients over-express the apoptosis- and cytotoxicity-related molecules. Medical Microbiology and Immunology,\u00a0208(6), 835\u2013844.","DOI":"10.1007\/s00430-019-00625-6"},{"issue":"4","key":"22_CR36","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s13311-015-0369-3","volume":"12","author":"R Boostani","year":"2015","unstructured":"Boostani, R., Vakili, R., Hosseiny, S. S., Shoeibi, A., Fazeli, B., Etemadi, M. M., et al. (2015). Triple therapy with prednisolone, Pegylated interferon and sodium valproate improves clinical outcome and reduces human T-cell leukemia virus type 1 (HTLV-1) Proviral load, tax and HBZ mRNA expression in patients with HTLV-1-associated myelopathy\/tropical spastic Paraparesis. Neurotherapeutics, 12(4), 887\u2013895.","journal-title":"Neurotherapeutics"},{"issue":"1\u20132","key":"22_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2012.05.004","volume":"250","author":"H Rafatpanah","year":"2012","unstructured":"Rafatpanah, H., Rezaee, A., Etemadi, M. M., Hosseini, R. F., Khorram, B., Afsahr, L., et al. (2012). The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. Journal of Neuroimmunology, 250(1\u20132), 87\u201393.","journal-title":"Journal of Neuroimmunology"},{"key":"22_CR38","doi-asserted-by":"crossref","unstructured":"Tegenge, M. A., Rajbhandari, L., Shrestha, S., Mithal, A., Hosmane, S., & Venkatesan, A. (2014). Curcumin protects axons from degeneration in the setting of local neuroinflammation. Experimental Neurology, 253102\u2013253110.","DOI":"10.1016\/j.expneurol.2013.12.016"},{"key":"22_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuropharm.2015.07.013","volume":"99","author":"M Mohajeri","year":"2015","unstructured":"Mohajeri, M., Sadeghizadeh, M., Najafi, F., & Javan, M. (2015). Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. Neuropharmacology, 99, 156\u2013167.","journal-title":"Neuropharmacology"},{"issue":"2","key":"22_CR40","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jss.2009.07.001","volume":"166","author":"MS Lin","year":"2011","unstructured":"Lin, M. S., Lee, Y. H., Chiu, W. T., & Hung, K. S. (2011). Curcumin provides neuroprotection after spinal cord injury. The Journal of Surgical Research, 166(2), 280\u2013289.","journal-title":"The Journal of Surgical Research"},{"issue":"9","key":"22_CR41","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00701-010-0702-x","volume":"152","author":"B Cemil","year":"2010","unstructured":"Cemil, B., Topuz, K., Demircan, M. N., Kurt, G., Tun, K., Kutlay, M., et al. (2010). Curcumin improves early functional results after experimental spinal cord injury. Acta Neurochirurgica, 152(9), 1583\u20131590. discussion 1590.","journal-title":"Acta Neurochirurgica"},{"issue":"4","key":"22_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4103\/0974-8520.110524","volume":"33","author":"N Hishikawa","year":"2012","unstructured":"Hishikawa, N., Takahashi, Y., Amakusa, Y., Tanno, Y., Tuji, Y., Niwa, H., et al. (2012). Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia. Ayu, 33(4), 499\u2013504.","journal-title":"Ayu"},{"issue":"6","key":"22_CR43","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00776-014-0633-0","volume":"19","author":"Y Nakagawa","year":"2014","unstructured":"Nakagawa, Y., Mukai, S., Yamada, S., Matsuoka, M., Tarumi, E., Hashimoto, T., et al. (2014). Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: A randomized, double-blind, placebo-controlled prospective study. Journal of Orthopaedic Science, 19(6), 933\u2013939.","journal-title":"Journal of Orthopaedic Science"},{"issue":"2","key":"22_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3109\/19390211.2015.1008611","volume":"13","author":"Y Panahi","year":"2016","unstructured":"Panahi, Y., Alishiri, G. H., Parvin, S., & Sahebkar, A. (2016). Mitigation of systemic oxidative stress by Curcuminoids in osteoarthritis: Results of a randomized controlled trial. Journal of Dietary Supplements, 13(2), 209\u2013220.","journal-title":"Journal of Dietary Supplements"},{"issue":"11","key":"22_CR45","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ptr.5174","volume":"28","author":"Y Panahi","year":"2014","unstructured":"Panahi, Y., Rahimnia, A. R., Sharafi, M., Alishiri, G., Saburi, A., & Sahebkar, A. (2014). Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial. Phytotherapy Research, 28(11), 1625\u20131631.","journal-title":"Phytotherapy Research"},{"issue":"6","key":"22_CR46","first-page":"1192","volume":"17","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar, A., & Henrotin, Y. (2016). Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and meta-analysis of randomized controlled trials. Pain Medicine, 17(6), 1192\u20131202.","journal-title":"Pain Medicine"}],"container-title":["Advances in Experimental Medicine and Biology","Natural Products and Human Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-73234-9_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T01:07:03Z","timestamp":1652404023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-73234-9_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030732332","9783030732349"],"references-count":46,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-73234-9_22","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"3 January 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that there is no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This clinical trial study was registered and approved by the Biomedical Research Ethics Committee at Mashhad University of Medical Sciences (MUMS, Mashhad-Iran) (no: 922212). All HAM\/TSP patients gave informed consent for blood donating and also for the inclusion of personal data before the study started.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standards"}}]}}